bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
4.090
-0.250 (-5.76%)
Apr 23, 2025, 4:00 PM EDT - Market closed
bluebird bio Stock Forecast
BLUE's stock price has decreased by -78.55% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for bluebird bio stock have an average target of 44.6, with a low estimate of 5.00 and a high estimate of 120. The average target predicts an increase of 990.46% from the current stock price of 4.09.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for bluebird bio stock from 7 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 7 | 6 | 6 | 6 | 5 | 5 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 9 | 9 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $40 → $8 | Buy | Maintains | $40 → $8 | +95.60% | Mar 31, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $40 → $5 | Hold | Maintains | $40 → $5 | +22.25% | Feb 24, 2025 |
| JP Morgan | JP Morgan | Sell → Hold Upgrades n/a | Sell → Hold | Upgrades | n/a | n/a | Feb 24, 2025 |
| Barclays | Barclays | Buy Maintains $2 → $40 | Buy | Maintains | $2 → $40 | +878.00% | Dec 31, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $80 | Hold | Reiterates | $80 | +1,855.99% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
266.99M
from 83.81M
Increased by 218.58%
Revenue Next Year
265.57M
from 266.99M
Decreased by -0.53%
EPS This Year
-9.79
from -24.84
EPS Next Year
-11.73
from -9.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 403.0M | 296.1M | 445.7M | ||
| Avg | 267.0M | 265.6M | 357.8M | ||
| Low | 147.1M | 220.5M | 271.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 380.9% | 10.9% | 67.8% | ||
| Avg | 218.6% | -0.5% | 34.7% | ||
| Low | 75.5% | -17.4% | 2.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.68 | -5.25 | -0.43 | ||
| Avg | -9.79 | -11.73 | -0.47 | ||
| Low | -23.13 | -17.64 | -0.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.